June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Activation of Pyruvate Kinase M2 (PKM2) attenuates inflammatory response in experimental bacterial endophthalmitis
Author Affiliations & Notes
  • Sukhvinder Singh
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Zeeshan Ahmad
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Susmita Das
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Ashok Kumar
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Footnotes
    Commercial Relationships   Sukhvinder Singh None; Zeeshan Ahmad None; Susmita Das None; Ashok Kumar None
  • Footnotes
    Support  NIH grant R01EY026964, R01EY027381, and R21AI140033
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4378. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sukhvinder Singh, Zeeshan Ahmad, Susmita Das, Ashok Kumar; Activation of Pyruvate Kinase M2 (PKM2) attenuates inflammatory response in experimental bacterial endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4378.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recently, we performed global metabolomics and transcriptomic analyses to determine key signaling pathways perturbed during experimental Staphylococcus (S) aureus endophthalmitis. The integrated data approach revealed increased glycolysis in infected mouse retina and bone marrow-derived macrophages (BMDMs). As pyruvate kinase isozyme type M2 (PKM2) is a key regulator of glycolysis and oxidative phosphorylation, the aim of this study is to investigate the role of PKM2 in bacterial endophthalmitis.

Methods : Bacterial endophthalmitis was induced in C57BL/6 mice by intravitreal (IVT) injection of S. aureus (SA) strain, RN6390. The physiological roles of PKM2 isoforms were determined by using its activator ML265 which promotes the tetrameric form of PKM2. ML265 is injected in the mouse eye at 6h post-SA infection. Disease progression was evaluated by a daily eye exam, ERG analysis, and bacterial burden and inflammatory cytokines assessment. Mechanistic studies were performed using cultured human retinal Müller glia, BMDMs, and neutrophils by challenging them with S. aureus in the presence or absence of ML265.

Results : Our temporal transcriptomic and metabolomics analyses revealed a time-dependent increase in genes and metabolites regulating glycolysis, respectively. Interestingly, intravitreal administration of PKM2 activator (ML265) resulted in diminished the severity of endophthalmitis as evidenced by decreased corneal haze, opacity, and hypopyon. The ML265-treated mice eyes exhibited reduced bacterial burden, neutrophil infiltration, and inflammatory mediators resulting in preserved retinal function. Moreover, PKM2 activator treatment in BMDMs, neutrophils, and Müller glia showed attenuated HIF-1α expression and inflammatory cytokines milieu.

Conclusions : Our study demonstrates that PKM2-mediated glycolytic reprogramming influences the innate immune response and its small molecule activator (ML265), negatively regulates the inflammation, and ameliorates the endophthalmitis severity. Therefore, modulation of the glycolytic enzyme “PKM2” could be used as an anti-inflammatory therapy to improve visual outcomes in bacterial endophthalmitis.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×